Clinical Trial Update: Iressa as Second Line Therapy in Advanced NSCLC-Asia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update showing Iressa as second-line therapy for advanced non-small cell lung cancer in Asia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC | Phase 3 | Status: COMPLETED